Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kyowa Hakko Kirin Pledges To Become Japan’s Top Biotech-based Pharma – Bio Japan

This article was originally published in PharmAsia News

Executive Summary

YOKOHAMA, Japan - Yuzuru Matsuda, president and CEO of Kyowa Hakko Kirin Co., said his company aimed to become "the top-class global biotechnology-based pharma that does research and development in the area of life sciences out of Japan, continuously making innovative contributions with antibody drugs." Matsuda spoke to an audience at Bio Japan in Yokohama Oct. 17

You may also be interested in...



Kirin Pharma Exec Tamao Watanabe On U.S. Biotech-Japan Pharma Collaborations: An Interview with PharmAsia News (Part 2 of 2)

Tokyo-based Kirin Pharma, which plans to merge with Kyowa Hakko Oct. 1, has done some 35 partnerships since parent company Kirin Brewery entered the pharmaceutical business in 1982. Tamao Watanabe, Kirin Pharma's senior manager of business development for the licensing section in the business development department, recently sat down with PharmAsia News' Tokyo bureau to talk about its partnership with North Carolina-based biotech venture Argos Therapeutics and how to make Japan-Western biotech partnerships work.

Japanese Kyowa's Antibody Technology Could Mean Cheaper Development Costs For Amgen - Analysts

TOKYO - The size of the up-front payment that Amgen provided Kyowa Hakko Kogyo this week to gain development and commercialization rights to the Phase I humanized monoclonal antibody KW-0761 for most of the world - except Japan, Korea, China and Taiwan - indicates strong interest in the Japanese company's Potelligent technology, experts say

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

AG002833

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel